Program
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024
Its studies are mostly in Carcinoma, Neuroendocrine · Melanoma · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms, led by Nanjing Leads Biolabs.
Drug pageAnti-PD-L1/4-1BB Bispecific Antibody LBL-024: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Leads Biolabs | 1010 open or running | phase 3since Jul 17, 2026 | Nov 17, 2021 | Dec 2026phase 2 · NCT05170958 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 17, 2021First study: phase 2 study in Advanced Solid TumorFirst studyNCT05170958 · 396 planned · China
- Nov 27, 2023Phase 2 study in Advanced Neuroendocrine CarcinomaNCT06157827 · 178 planned · China
- Jun 17, 2025Phase 2 study in Ovarian NeoplasmsNCT07042802 · 180 planned · China
- Jul 25, 2025Phase 2 study in Advanced MelanomaNCT07099430 · 280 planned · China
- Aug 1, 2025Phase 2 study in Advanced Solid TumourNCT07111546 · 140 planned · China
- Dec 2, 20252 phase 2 studiesNCT07281976, NCT07331155
- Jan 29, 2026Phase 2 study in Advanced Solid TumourNCT07390383 · 110 planned · China
- Jul 17, 2026Phase 3 study in Advanced Extrapulmonary Neuroendocrine CarcinomaPhase 3 reachedNCT07720193 · 280 planned · China
- Aug 25, 2026Phase 2 study in Colorectal NeoplasmsNCT07791758 · 369 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Solid TumorNCT05170958
- Dec 28, 2026Primary completion: phase 2 study in Advanced Neuroendocrine CarcinomaNCT06157827
- Oct 30, 2027Primary completion: phase 2 study in Advanced MelanomaNCT07099430
- Dec 25, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT07042802
TargetBeta
“A tetravalent bispecific antibody targeting the immunosuppressive ligand programmed death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| acasunlimabrule | Genmab | phase 3 | 6 |
| Anti-CD137/PD-L1 Bispecific Antibody FS222 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07791758Colorectal Neoplasms · China | 2 | Recruiting | Sep 4, 2030 | 369 |
| NCT07720193Advanced Extrapulmonary Neuroendocrine Carcinoma · China | 3 | Not yet recruiting | Dec 22, 2030 | 280 |
| NCT07390383Advanced Solid Tumour · China | 2 | Recruiting | May 30, 2028 | 110 |
| NCT07331155Advanced Solid Tumour · China | 2 | Recruiting | Dec 26, 2028 | 110 |
| NCT07281976Triple Negative Breast Neoplasms · China | 2 | Recruiting | Dec 31, 2027 | 220 |
| NCT07111546Advanced Solid Tumour · China | 2 | Recruiting | Dec 26, 2027 | 140 |
| NCT07099430Advanced Melanoma · China | 2 | Recruiting | Oct 30, 2027 | 280 |
| NCT07042802Ovarian Neoplasms · China | 2 | Recruiting | Dec 25, 2027 | 180 |
| NCT06157827Advanced Neuroendocrine Carcinoma · China | 2 | Recruiting | Dec 28, 2026 | 178 |
| NCT05170958Advanced Solid Tumor · China | 2 | Recruiting | Dec 2026 | 396 |
How it is read
Names in the registry
- “LBL-024 for Injection”, 10 entries
Conditions, from the studies’ own filings
- Carcinoma, Neuroendocrine, 2 studies
- Melanoma, 1 study
- Colorectal Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.